Patients with poor prognostic features in leukemia have high mortality rates; therefore, scientifically proven treatment plans have important implications on the survival of the patients. Detection of relevant gene mutations may help the physicians develop rational treatment plans and promptly adjust medication dose according to the change in drug sensitivity caused by mutations in the course of the treatment, providing monitoring data for prognosis effects.

       FLT3 is a proto-oncogene in the tyrosine kinases Class Ⅲ family and is one of the most frequently mutated genes in AML. FLT3 mutations mainly include internal tandem duplications(ITD) and D835 mutations; ITD mutations are found in 17-26% of AML patients and are independent adverse prognostic factors. Leveraging common PCR technology, FLT3-ITD mutation assay kit detects FLT3-ITD mutations in patients through specific primer design.

       JAK is a family of tyrosine protein kinases and after binding to hematopoietic growth factor receptors, it affects gene transcriptional regulation via signal transducers and activators of transcription. JAK2 mutations can result in erythropoietin-independent erythropoiesis of hematopoietic cells, hypersensitivity of growth factors and high expression of PRV1 genes, etc. The revised 2008 WHO classification system identified JAK2 as the major diagnostic criterion for chronic myeloproliferative disorders(MPD).

Product list



Pack size



FLT3-ITD mutation assay kit

20 Tests/Kit

General PCR


JAK2-V617 gene mutation assay kit

20 Tests/Kit

Fluorescent PCR/General PCR


JAK2-V617 gene mutation assay kit

20 Tests/Kit